• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Surgical

Cerus lands additional $15m in government funding

May 17, 2018 By Sarah Faulkner

Cerus Corp.

Cerus (NSDQ:CERS) landed a $15 million amendment to its contract with the U.S. Dept. of Health & Human Services’ Biomedical Advanced Research and Development Authority, bringing the total potential value of its deal to $201 million. The expanded agreement is designed to support additional clinical trials of the company’s Intercept blood transfusion technology. Cerus’ Phase III […]

Filed Under: Cardiovascular, Clinical Trials, Featured, Funding Roundup, Surgical, Wall Street Beat Tagged With: Cerus Corp.

This new technology could help surgeons clear out leftover cancer cells

March 27, 2018 By Sarah Faulkner

In some instances, as many as 30% of patients need repeat surgeries get rid of cancerous cells initially left behind. The team from Lumicell wants to change that — and improve outcomes for cancer patients. [Image by MDO art director Matthew Claney] After his wife died of breast cancer in 2003, David Lee stepped away from […]

Filed Under: Diagnostics, Drug-Device Combinations, Featured, Imaging, Oncology, Pharmaceuticals, Surgical Tagged With: Lumicell

Tela Bio lands $1m investment for surgical implants

March 27, 2018 By Sarah Faulkner

Tela Bio

Privately-held Tela Bio said this week that it landed a $1 million investment from ProMedica, a not-for-profit healthcare group serving northwest Ohio and southern Michigan. According to the deal, Tela Bio and ProMedica Innovations Venture Fund plan to strike a strategic relationship to educate surgical specialists at the ProMedica Hernia Center using Tela Bio’s regenerative […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Implants, Surgical Tagged With: telabio

Facing legal woes and SEC probe, Ocular Therapeutix posts mixed Q4

March 8, 2018 By Sarah Faulkner

Ocular Therapeutix

Shares in Ocular Therapeutix (NSDQ:OCUL) rose this morning after the company beat expectations on Wall Street with its fourth quarter earnings, but missed analysts’ sales estimates. The company is facing a slew of class action suits from investors, as well as a probe by the Securities and Exchange Commission regarding its post-surgical pain relief implant, Dextenza. […]

Filed Under: Drug-Device Combinations, Featured, Legal News, MassDevice Earnings Roundup, Optical/Ophthalmic, Pharmaceuticals, Surgical, Wall Street Beat Tagged With: Ocular Therapeutix

Study: Hill-Rom’s Metaneb System lowers risk of post-operative pulmonary complications

February 28, 2018 By Sarah Faulkner

Hill-Rom's Metaneb system

Researchers at the 47th Society of Critical Care Medicine reported this week that Hill-Rom‘s (NYSE:HRC) Metaneb System may help reduce the incidence of post-operative pulmonary complications in high-risk patients. A 419-patient study found that patients using the Metaneb System combined with standard respiratory therapy spent 1.6 fewer days in the hospital on average compared to […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory, Surgical, Wall Street Beat Tagged With: Hill-Rom Holdings

Icon Bioscience wins FDA nod for long-acting cataract surgery drug

February 12, 2018 By Sarah Faulkner

Icon Bioscience

Icon Bioscience said today that the FDA has approved its application for Dexycu, a long-acting therapy designed to treat inflammation in patients who have had cataract surgery. More than four million cataract surgeries are performed each year in the U.S., according to the privately-held biopharma company, and most patients treat inflammation in their eyes using […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Pharmaceuticals, Regulatory/Compliance, Surgical Tagged With: iconbioscience

Medtech stories we missed this week: Jan. 19, 2018

January 19, 2018 By Danielle Kirsh

missed medtech aug 4

From Privi Medical’s FDA clearance to OrthoXel getting FDA clearance and CE Mark approval, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Privi Medical wins FDA nod for hemorrhoid device Privi Medical has received FDA clearance for its Instalief Hemorrhoids Treatment device, according to a Jan. 18 news […]

Filed Under: Featured, Food & Drug Administration (FDA), Implants, Orthopedics, Regulatory/Compliance, Surgical Tagged With: Avacen Medical, BioPoly, Centric Medical, medtech, OrthoXel, Privi Medical, Sealantis, Zoll Medical Corp.

Medtech stories we missed this week: Dec. 22, 2017

December 22, 2017 By Danielle Kirsh

missed-medtech-0922

From Hepa Wash’s new collaboration to Stimwave’s FDA clearance, here are five medtech stories we missed this week but thought were still worth mentioning. 1. Hepa Wash collaborates with GALS program Hepa Wash announced in a Dec. 7 press release that it has collaborated with the German Accelerator Life Sciences (GALS) program to expand its […]

Filed Under: Diagnostics, Featured, Food & Drug Administration (FDA), Hospital Care, Imaging, Implants, Pain Management, Regulatory/Compliance, Surgical Tagged With: Camber Spine, Hepa Wash, In2Bones, medtech, NanoVibronix, Stimwave

Medtech stories we missed this week: Dec. 8, 2017

December 8, 2017 By Danielle Kirsh

medtech missed

From Minimus Spine’s European distribution deal to Stimwave receiving FDA clearance, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Minimus Spine inks EU distribution deal Minimus Spine announced in a Dec. 4 press release that it has signed its first European distribution deal with Italian company Moss […]

Filed Under: Business/Financial News, Cardiovascular, Diagnostics, Featured, Food & Drug Administration (FDA), Oncology, Pain Management, Regulatory/Compliance, Surgical, Technology Tagged With: Cagent Vascular, CSA Medical, Dermacon, Elanix, InspireMD, Life Spine Inc., medtech, Minimus Spine, Stimwave

Pacira to invest up to $25m in surgical reconstruction company

October 25, 2017 By Sarah Faulkner

Pacira Pharmaceuticals

Pacira Pharmaceuticals (NSDQ:PCRX) plans to invest up to $25 million in privately-held surgical reconstruction company Tela Bio, the company said today. Pennsylvania-based Tela Bio has a portfolio of reinforced bioscaffold products, called OviTex, which combine biologic and synthetic materials in an embroidered implant that allows fluid and cells to move freely through the device. The implants […]

Filed Under: Featured, Funding Roundup, Pharmaceuticals, Surgical, Wall Street Beat Tagged With: Pacira Pharmaceuticals, telabio

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Interim pages omitted …
  • Page 7
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS